Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Life Science Institute to Test Muse Cell Therapy in ALS
January 29, 2021
- Ono Apologizes over Arrest of 2 Employees on Bribery Allegations
January 29, 2021
- Forxiga Gets Priority Review Status for CKD in Japan: AZ
January 29, 2021
- SymBio, Univ. of Tokyo Jointly Explore New Indications for Bendamustine, Rigosertib
January 29, 2021
- Sawai Gains Japan Rights for Israeli Firm’s Digital Device for Migraines; Eyes Filing in 2022
January 29, 2021
- Nichi-Iko Puts Mesalazine Supply on Hold over Variations in API Content in Latest Lots
January 29, 2021
- Supply Control for Beova to Last until FY2022: Kyorin/Kissei
January 29, 2021
- Pfizer, Viatris Control Shipment of 9 APIs over Kobayashi Kako, Nichi-Iko Recall Havoc
January 29, 2021
- Bristol Myers Donates 5.5 Billion Yen to Kyoto University to Support I/O Research
January 28, 2021
- Kobayashi Kako Issues Yet Another Recall, Now for 12 APIs/21 Products
January 28, 2021
- MSD’s Anti-MRSA Drug Cubicin Filed for Pediatric Use
January 28, 2021
- Chugai Drops Suit over Edirol Substance Patent, Row Continues for Method-of-Use
January 28, 2021
- BioAge Gets US/Europe Rights for Shionogi’s COVID-19 Treatment
January 27, 2021
- Pfizer’s Methotrexate 1000 mg Hit by Stock-Out on Flaws at German Manufacturing Site
January 27, 2021
- Kenei to Fight Maruho’s Claim over Healmild Trademark to the End
January 27, 2021
- Mitsubishi Tanabe Snaps Up Worldwide Rights for Antibody Drug Candidate for Autoimmune Diseases
January 27, 2021
- Nippon Express’s 3rd Pharma Distribution Hub Launched in Toyama
January 27, 2021
- Chugai’s FoundationOne Approved as CDx for Larotrectinib in Japan
January 26, 2021
- Health Damages Linked to Kobayashi Kako Mix-Up Rise to 215
January 26, 2021
- Mitsubishi Tanabe Gets US Commercial Rights for Aquestive’s ALS Med
January 25, 2021
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…